Status: Recruiting
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy for patients with intervenable oligometastatic (stage IV) cancer of the upper gastrointestinal (GI) tract and undetectable ctDNA at the time of randomization after a three-month induction chemotherapy period.
Participants needed: 54
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Yale UniversityUpdated: Jun 22, 2026Locations: 1
Eligibility criteria
Has a primary diagnosis of AJCC 8th Edition Stage IV esophageal or gastroesophag... [+22]
Has a positive urine pregnancy test within 3 days prior to randomization or trea... [+21]